Oruka Therapeutics (NASDAQ:ORKA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Oruka Therapeutics (NASDAQ:ORKA - Free Report) from a hold rating to a sell rating in a research note published on Saturday.

Several other research firms have also recently commented on ORKA. BTIG Research initiated coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a "buy" rating on the stock. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Trading Down 2.4%

Shares of NASDAQ:ORKA traded down $0.31 during trading on Friday, hitting $12.56. 131,591 shares of the company's stock traded hands, compared to its average volume of 221,429. The company has a 50-day moving average price of $10.28 and a 200-day moving average price of $13.12. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The company has a market cap of $470.26 million, a price-to-earnings ratio of -2.01 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. On average, analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new stake in Oruka Therapeutics in the 4th quarter valued at $54,000. AlphaCentric Advisors LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $119,000. AlphaQuest LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter valued at $168,000. Cannon Global Investment Management LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter valued at $195,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at $236,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.